A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

Trial Details

NCT ID

NCT06764485

Phase

PHASE3

Sponsor

Celgene

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

• BMS-986365
• Enzalutamide
• Abiraterone
• Docetaxel
• Predinsone/Prednisolone

Locations (sample)

• Birmingham, Alabama, United States|33.52066,-86.80249
• Gilbert, Arizona, United States|33.35283,-111.78903
• Anaheim, California, United States|33.83529,-117.9145
• Los Angeles, California, United States|34.05223,-118.24368
• Aurora, Colorado, United States|39.72943,-104.83192

Key Eligibility Criteria

• Participants must have histologic or cytologic confirmation of adenocarcinoma of the prostate without small cell or neuro-endocrine features.
• Participants must have current evidence of metastatic disease documented by either bone lesions on radionuclide bone scan and/or soft tissue lesion…
• Participants must be asymptomatic or mildly symptomatic from prostate cancer with score on Brief Pain Inventory - Short Form (BPI-SF) that must be …
• Participants must have had previous treatment with an androgen receptor pathway inhibitor (abiraterone, enzalutamide, apalutamide, or darolutamide).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.